- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659317
Opioid-Free Orthopaedics
A Double-Blinded Randomized Controlled Trial Examining Multimodal Opioid-Free Orthopaedic Procedures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Alexander Dawes
- Phone Number: 404-784-2402
- Email: adawes@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital
-
Contact:
- Eric Wagner, MD
- Email: eric.r.wagner@emory.edu
-
Atlanta, Georgia, United States, 30024
- Recruiting
- The Emory Clinic
-
Contact:
- Eric Wagner, MD
- Email: eric.r.wagner@emory.edu
-
Tucker, Georgia, United States, 30084
- Recruiting
- Emory Orthopedic and Spine Hospital
-
Contact:
- Eric Wagner, MD
- Email: eric.r.wagner@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient with advanced arthritis undergoing a total joint replacement (e.g. total shoulder arthroplasty, anatomic or reverse), in the primary setting.
- Any patient undergoing an orthopaedic procedure or surgery of their finger, hand, wrist, forearm, or elbow
- Any patient undergoing an orthopaedic procedure or surgery for their hip, knee, ankle or foot
- Patients who have exhausted 3+ months of nonoperative treatment to include activity modifications, optional corticosteroid injections, and physical therapy.
- Patients over the age of 18 years old that are willing to participate in the study and mentally capable to consent
Exclusion Criteria:
- Patients with concurrent and significant injuries to other bones or organs, local infections, history of alcohol or medical abuse, preoperative opioid use within 3 months of the surgery, advanced renal or liver disease, contraindication to receiving a nerve block, uncontrolled diabetes mellitus (HbA1C >9.0), or if a prior gastric ulcer precludes Aspirin and anti-inflammatory medications.i. Prior to inclusion, the patient will undergo blood testing to evaluate both kidney and liver function, including estimated glomerular filtration rate (GFR) as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
- Workman's compensation status, minors, vulnerable subjects, women who are pregnant, or those who are not willing to consent to participate in the study.
- Patients who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Opioid Group
Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety" Prescription: Oxycodone5 mg po q6 hours as needed for pain
|
Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
|
Experimental: Placebo Group
Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery "Safety" Prescription: Oxycodone5 mg po q6 hours as needed for pain
|
Encapsulated placebo tablets x24, to take po q6 hours as need for pain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pain (VAS) Score
Time Frame: Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
The investigators will assess patient postoperative pain utilizing a visual analog scale (VAS) for the first 14 days postoperatively.
They will also assess pain at each postoperative visit after at 6 weeks, 3 months, 6 months, 12 months, 24 months, and 60 months.
This scale will assess pain at 3 different timepoints throughout the day defined as morning, afternoon, and evening.
The pain scale will range from 0-10 with 10 being a worse outcome quantifying the highest pain rating.
|
Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient Satisfaction Scores
Time Frame: Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
Patients will be asked their overall level of satisfaction with the procedure and pain control. The investigators will use a rating scale with the following choices:
The scale has a maximum value of a patient stating they are doing much better than expected (5) and much worse as the minimum value (1) quantifying the worst outcome. Patients stating it is too soon to give an opinion is a null value. |
Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
Change in opioid consumption
Time Frame: Baseline, 60 months post operative
|
The investigators will assess the amount of opioids consumed utilizing total morphine equivalents as an equal metric to compare between patients.
It will also de assessed whether the patient utilized he safety/rescue prescription.
It will also be included the information on whether patients obtain a refill prescription.
Total consumption will be assessed by utilizing total morphine equivalents as the metric as stated previously with patients with higher values quantifying a worse outcome.
|
Baseline, 60 months post operative
|
Change in associated side effects
Time Frame: Postoperatively for the first 14 days, and then 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
The investigators will utilize a 0-10 scale for patient symptoms for feeling any of these side effects due to postoperative medication for the first 14 days and at each follow up visit.
We will assess only at each subsequent follow up visit 6 weeks, 3 months, 6 months, 12 months, 24 months, and 60 months so long as they are continuously taking medications associated with postoperative pain protocol.
Outcomes with a score of 10 will quantify a poor result and patients dealing with severe common side effects due to opioid medication.
|
Postoperatively for the first 14 days, and then 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
|
Change in Single Assessment Numeric Evaluation (SANE) score
Time Frame: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 60 months postoperative
|
The Single Assessment Numeric Evaluation (SANE) score requires the patient to rate their injured extremity 0-100 as a percentage of their function compared to normal.
The patient will be asked this question at the following timepoints: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months.
A rating of 0 is the minimum value and denotes the lowest possible value and worse outcome a patient can have on the scale.
|
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 60 months postoperative
|
Change in American Shoulder and Elbow Surgeons Index Scale (ASES)
Time Frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
|
The ASES is a survey designed to assess the condition of the shoulder.
This survey will only be utilized in the cases of patients with a shoulder pathology.
The survey will utilize the 10 components assessing the activities of daily living.
Scores range from 0 to 100 with a score of 0 denoting a worse shoulder condition.
The investigators will utilize this assessment at the following timepoints: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months.
|
baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
|
Change in European Quality of Life 5 dimension (EQ-5D)
Time Frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
|
The EQ-5D is one of the most commonly used assessments for measuring health and quality of life.
The EQ-5D will be assessed at the following timepoints: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months.
The assessment utilizes a scale of 0 to 1 with a score of 0 corresponding to death and 1 representing perfect health.
|
baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
|
Length of stay postoperative
Time Frame: End of the trial (up to 60 months post operative)
|
The investigators will assess length of stay as another outcome for surgery types that typically require admission to the hospital.
It will be assessed this once and collect data with regards to hospital stay following their discharge from the hospital.
A shorter time interval corresponds to a better outcome and those patients with a longer stay is a less desirable outcome.
|
End of the trial (up to 60 months post operative)
|
Number of complications
Time Frame: End of the trial (up to 60 months post operative)
|
The investigators will assess complications due to surgery such as reoperation, readmission, revision procedure, temporary or permanent nerve injuries, hematomas, superficial and deep infections, recurrent pain, fractures, and implant loosening and dislocations.
The assessment of these complications will happen as they occur and will be recorded as a descriptive and no true values will be recorded rather than the complication itself.
|
End of the trial (up to 60 months post operative)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Wagner, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000478
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Oxycodone 5 mg Oral Tablet
-
University of FloridaRecruiting
-
University of FloridaNational Institute on Drug Abuse (NIDA)Recruiting
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
William Beaumont HospitalsCompletedPost-operative Pain | Sinus SurgeryUnited States
-
Stanford UniversityMayo Clinic; University of British Columbia; Albert Einstein College of Medicine and other collaboratorsCompletedPain | Postoperative Pain | Sinusitis | Opioid Use | Opioid Abuse | Narcotic Use | Otolaryngologic DiseaseUnited States, Canada
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
Damanhour UniversityCompleted